オプションチェーンは、Eterna Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Eterna Therapeuticsの市場センチメントを評価します。.

Eterna Therapeutics (NASDAQ:ERNA) 株価情報, オプションチェーン

Eterna Therapeutics

Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Eterna Therapeutics Inc

-Bloomberg, citing people familiar with the matter

News

Rumors

JD.com Is Said to Revive Interest in Buying Germany's Ceconomy

Citigroup analyst Paul Lejuez downgrades Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) from Neutral to Sell and raises the price target from $19 to $23.

Downgrades

Price Target

Analyst Ratings

WRBY

Citigroup Downgrades Warby Parker to Sell, Raises Price Target to $23

Guidance

Boston Scientific Sees FY25 Adj. EPS $2.80-$2.87 vs $2.81 Est., Sees Q1 Adj. EPS $0.66-$0.68. vs $0.64 Est.

Indian Prime Minister Narendra Modi might meet with Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk during the former&#8217;s visit to the U.S. later this month, Indian local media reported on Wednesday.
What Happened: Modi is expected to be in the U.S. from February 12 to 14 on an invitation from President Trump and Musk will likely be part of a group of CEOs who will meet with Modi on Feb. 13, according to <a href="https://www.cnbctv18.com/world/teslas-elon-musk-likely-to-call-on-pm-narendra-modi-next-week-19552983.htm">a</a> CNBC TV-18 report.
Musk, who was slated to visit India to meet Modi in April, discarded the plan citing obligations at the EV company. Musk has previously talked about launching Tesla vehicles as well as his Starlink satellite Internet service in India.
A meeting between the billionaire and the Indian government, however, might not result in an immediate announcement of manufacturing in the country, the report said, citing sources. 
Tesla and SpaceX did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga</a>&#8216;s request for comment on the alleged meeting. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43486319/tesla-bear-expects-ev-giants-earnings-to-fall-below-bullish-estimates-in-2025-notes-majority-of-companys-revenues-come-from-car-deliveries" target="_blank" rel="noreferrer noopener">Tesla Bear Expects EV Giant's Earnings To Fall Below Bullish Estimates In 2025, Notes Majority Of Company's Revenues Come From Car Deliveries</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

Tech

TSLA

Elon Musk To Reportedly Meet Indian PM Modi Later This Month: Tesla, Starlink Launch Talks On Radar?

MKTX

MarketAxess Sees Total Average Daily Volume Of $38.9B In January 2025, Up 22% Compared To The Prior Year, And 22% Compared To December 2024 Levels

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.66 by 6.06 percent. This is a 27.27 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $4.561 billion which beat the analyst consensus estimate of $4.424 billion by 3.09 percent. This is a 22.44 percent increase over sales of $3.725 billion the same period last year.

Earnings

Earnings Beats

Boston Scientific Q4 2024 Adj. EPS $0.70 Beats $0.66 Estimate, Sales $4.561B Beat $4.424B Estimate

The Offering is being conducted on a firm commitment basis. The ordinary shares are expected to commence trading on Nasdaq Capital Market under the ticker symbol "PLUT" on February 5, 2025.

IPOs

PLUT

Plutus Financial Prices IPO Of 2.10M Ordinary Shares At $4 Per Ordinary Share, For Total Gross Proceeds Of $8.4M

Citigroup analyst Filippo Falorni upgrades Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) from Sell to Neutral and raises the price target from $47 to $57.

Upgrades

Citigroup Upgrades Molson Coors Beverage to Neutral, Raises Price Target to $57

ZDGE

Zedge Also Expects To Benefit From The Completion (In April 2025) Of Gurushots Employee Retention Bonuses, Which Will Further Reduce Gurushots (And Zedge's) Annualized Expense Run-rate By ~$1.2M Beginning In Q4

<a href="https://www.uber.com/us/en/u/waymo-on-uber/" title="https://www.uber.com/us/en/u/waymo-on-uber/">https://www.uber.com/us/en/u/waymo-on-uber/</a>

UBER

Uber Says Waymo Coming To Uber, Launching In Austin, TX, Coming Soon To Atlanta, GA

Citigroup analyst Christopher Danely upgrades NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) from Sell to Neutral and raises the price target from $200 to $210.

NXPI

Citigroup Upgrades NXP Semiconductors to Neutral, Raises Price Target to $210

Zedge Discloses Additional Restructuring Initiatives, Mainly The Closure Of Its Norway Operations And Estimates Estimated Total Global Restructuring And Other Cost Reductions To Save $3.9M-$4.1M Annually Relative To Q1 FY25 Run Rate - FY24 Free Cash Flow Of $4.7M

Kennametal Sees Q3 Sales Of $480M - $500M Vs. $517.58M Est; Q3 Adj EPS Of $0.20 - $0.30 Vs. $0.38 Est.

AZZ Expects FY26 Sales $1.625B - $1.725B (Est $1.681B), Adj EPS Of $5.50 - $6.10 (Est $5.82)

Kennametal Sees FY25 Sales Of $1.950B - $2.0B Vs. $2.03B; Adj EPS Of $1.05 - $1.30 Vs. $1.44 Est.

Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.19 by 10.53 percent. This is a 16.67 percent increase over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $17.10 billion which beat the analyst consensus estimate of $15.20 billion by 12.53 percent. This is a 9.19 percent increase over sales of $15.66 billion the same period last year.

Banco Santander Q4 GAAP EPS $0.21 Beats $0.19 Estimate, Sales $17.10B Beat $15.20B Estimate

Health Care

General

Cencora Expects 2025 Revenue Growth Of 8%-10%, From The Previous Range Of 7%-9%

Fiscal Year 2025 Expectations on an Adjusted (non-GAAP) Basis
On January 2, 2025, Cencora updated its fiscal year 2025 financial guidance only for adjusted diluted EPS following the closing of the RCA acquisition to reflect the expected contribution from RCA and momentum in the U.S. Healthcare Solutions reportable segment.
Cencora is now updating its fiscal year 2025 adjusted diluted EPS guidance to better reflect the continued momentum in the U.S. Healthcare Solutions reportable segment. Additionally, the Company is updating its fiscal year 2025 financial guidance expectations for revenue, operating income and net interest expense to reflect the impact of the RCA acquisition and the continued momentum in the U.S. Healthcare Solutions segment. The Company now expects:
<ul>
<li>Revenue growth to be in the range of 8 to 10 percent, from the previous range of 7 to 9 percent;
<ul>
<li>U.S. Healthcare Solutions revenue growth to be in the range of 9 to 11 percent, from the previous range of 7 to 9 percent;</li>
<li>International Healthcare Solutions revenue growth to be in the range of 4 to 5 percent, from the previous range of 7 to 9 percent;</li>
</ul>
</li>
<li>Adjusted diluted EPS to be in the range of $15.25 to $15.55, up from the previous range of $15.15 to $15.45 provided on January 2, 2025 and the initial guidance range of $14.80 to $15.10.</li>
</ul>
Additional expectations now include:
<ul>
<li>Adjusted consolidated operating income growth to be in the range of 11.5 to 13.5 percent, from the previous range of 5 to 6.5 percent;
<ul>
<li>U.S. Healthcare Solutions segment operating income growth to be in the range of 14.5 to 16.5 percent, from the previous range of 5 to 6.5 percent;</li>
<li>International Healthcare Solutions segment as reported operating income growth to be flat, from the previous range of 5 to 6.5 percent;
<ul>
<li>On a constant currency basis, International Healthcare Solutions segment operating income growth to be approximately 5 percent;</li>
</ul>
</li>
</ul>
</li>
<li>Net interest expense to be in the range of $290 million to $310 million, from the previous range of $150 million to $170 million; and</li>
<li>Weighted average diluted shares outstanding is expected to be under 196 million, from the previous expectation of approximately 196 million.</li>
</ul>

Cencora Expects 2025 Adjusted EPS Of 15.25-$15.55 Versus Prior Guidance Of $15.15-$15.45 And Consensus of $15.28.

RXO Sees Q1 FY25 Adj. EBITDA Of $20M-$30M, Brokerage Gross Margin Of 12%-14%

The dividend is payable March 31, 2025, to shareholders of record on March 7, 2025.

Dividends

Trane Technologies Boosts Quarterly Dividend By 12% From $0.84 To $0.94 Per Share

Eterna (ERNA) Therapeutics has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock ...

Eterna regains compliance with Nasdaq

Eterna Therapeutics announces up to $1 million stock repurchase program

Eterna (ERNA) Therapeutics announced that its Board of Directors has authorized a stock repurchase program of up to $1M of the company's outstandin...

Eterna announces up to $1M stock repurchase program

Eterna (ERNA) Therapeutics announced it will investigate the ability of its lead iMSC-based cell therapy, ERNA-101, to induce and modulate antitumo...

Eterna launches research to evaluate ERNA-101

Eterna Therapeutics ( ($ERNA) ) has provided an update. Eterna Therapeutics Inc. has faced a compliance issue with the Nasdaq Stock Market due to i...

Eterna Therapeutics Faces Nasdaq Compliance and Board Changes

Eterna (ERNA) Therapeutics announced positive results from a preclinical study on the company's lead cell therapy product, ERNA-101, which is desig...

Eterna announces preclinical study results on ERNA-101

Firefly Neuroscience, Eterna Therapeutics, and Nature's Miracle Holding are the 3&nbsp;Penny Stocks&nbsp;to watch on January 16, 2025, based on&nbs...

3 Penny Stocks to Watch Now, 1/16/25

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Eterna (ERNA) Therapeutics announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company's scientific advisory boa...

Eterna appoints Zeldis, Sather to scientific advisory board

AIFF

ANIX

AZTR

BDTX

ERNA

EVAX

GBIO

GTBP

IBIO

KAPA

KROS

LEXX

NMHI

OSTX

PHIO

RGNX

SLRX

SLXN

SNGX

TNFA

Press Releases

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

Management

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Markets

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Comments

Eterna Therapeutics

Eterna Therapeutics (ERNA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル